Last edition
News about "Cristian Massacesi"
US FDA Grants Accelerated Approval to BMS' ZENBEXUS for Multiple Myeloma
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) ZENBEXUS, a first-in-class CELMoD therapy combined with daratumumab and dexamethasone for multiple myeloma.
Cristian Massacesi | 14/08/2026 | By News Bureau
Bristol Myers Squibb Secures FDA Priority Review for Camzyos
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s supplemental New Drug Application (NDA) for Priority Review (PR) of Camzyos (mavacamten) to treat adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Cristian Massacesi | 02/06/2026 | By News Bureau | 159
Bristol Myers Squibb reported Phase 3 SUCCESSOR-2 results showing that mezigdomide reduced the risk of disease progression or death by more than 50% versus standard of care in relapsed or refractory multiple myeloma, marking the first successful Phase 3 CELMoD trial presented at ASCO 2026.
Cristian Massacesi | 30/05/2026 | By News Bureau | 106
Bristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Trial Results
Bristol Myers Squibb reports positive Phase 3 SCOUT-HCM results showing Camzyos efficacy and safety in adolescents with oHCM, achieving significant LVOT reduction with no new safety concerns.
Cristian Massacesi | 30/03/2026 | By News Bureau | 190
Bristol Myers Squibb Reports Positive Phase II Data for Reblozyl in Alpha-Thalassemia
Bristol Myers Squibb’s Phase II trial shows Reblozyl significantly improved haemoglobin levels in non-transfusion-dependent patients and reduced transfusion burden in transfusion-dependent alpha-thalassemia, meeting all primary and key secondary endpoints.
Cristian Massacesi | 25/02/2026 | By News Bureau | 213
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy